Toby Maher, Royal Brompton Hospital, London, met with us at ERS 2019 in Madrid to discuss the results of a Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD).
1. What is the definition of unclassifiable interstitial lung disease (uILD) and what proportion of ILD patients are considered unclassifiable? (0:05)
2. What is the current standard of care for patients with progressive fibrosing uILD? (0:44)
3. Could you tell us a little about the design and findings of the recent study investigating pirfenidone in patients with progressive fibrosing uILD? (1:11)
4. Which patients are most likely to respond to this treatment approach? (1:55)
5. What further studies are planned? (2:33)
Speaker disclosures: Toby Maher has received consultancy fees, travel expenses and honoraria from Roche and Boehringer Ingelheim.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
Share this Video
Related Videos In Interstitial Lung Disease
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Junelle Speller – The Pulmonary Fibrosis Foundation Community Registry
The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help advance medical research. It was a pleasure to talk with PFF Vice President, Junelle Speller […]
Junelle Speller: Pulmonary Fibrosis Foundation – Unmet Needs in Pulmonary Fibrosis and Interstitial Lung Disease
The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help advance medical research. touchRESPIRATORY were delighted to talk to PFF Vice President, Junelle Speller around […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!